On October 20, 2026, the trial status for NCT06531499 was reported as active, not recruiting. The study, titled "A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naive Adults With Metastatic Castration-resistant Prostate Cancer," also known as the RADIODOSE study, is a Phase 1 trial. It examines radiation dosimetry, safety, and tolerability of extended treatment with 177Lu vipivotide tetraxetan in chemo-naive adults with metastatic castration-resistant prostate cancer. Degarelix, an approved compound, is associated with this trial record. The current status indicates the study is no longer enrolling new participants but remains ongoing for those already involved. No results or outcome data were included in this update. The trial identifier is NCT06531499, and further details are available through the official registry listing. This update reflects only the status and phase information provided as of the reporting date. No additional efficacy, safety outcomes, or dosing information was disclosed in this event record. Readers seeking more background on degarelix can consult the compound overview for further context.
Degarelix-Linked Trial NCT06531499 Now Active, Not Recruiting as of Oct 2026
See the full degarelix overview
Source: https://clinicaltrials.gov/study/NCT06531499